Novartis gets EU approval for Cushing's drug
ZURICH (Reuters) - Swiss drug maker Novartis AG (NOVN.VX) said on Wednesday it has won European Union approval for its Signifor as the first medical therapy for Cushing's disease, a rare hormonal disorder.
Signifor, which is designed for Cushing's disease patients who cannot have surgery or for whom surgery has not been successful, had already won a green light from the European Medicines Agency (EMA) in January.
Cushing's is caused by a small tumour of the pituitary gland making too much of a hormone. Standard treatment is surgical removal of the tumour, but this does not always work.
- Tweet this
- Share this
- Digg this
- UPDATE 1-Don't mess with nuclear Russia, Putin says
- Exclusive - Over 100 Russian soldiers killed in single Ukraine battle - Russian rights activists
- Scotland's pro-independence campaign gains on final TV debate - poll
- Iceland says eruption over, lifts all airspace restrictions
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |